Fostemsavir: a first-in-class HIV-1 attachment inhibitor
暂无分享,去创建一个
[1] M. Kozal,et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 , 2021, AIDS.
[2] M. Kozal,et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. , 2020, The lancet. HIV.
[3] M. Kozal,et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. , 2020, The New England journal of medicine.
[4] Alon Herschhorn,et al. Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529 , 2017, Nature chemical biology.
[5] Samit R. Joshi,et al. Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial , 2017, Antiviral therapy.
[6] Samit R. Joshi,et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. , 2015, The lancet. HIV.
[7] M. Krystal,et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. , 2012, The Journal of infectious diseases.
[8] N. Meanwell,et al. In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 , 2012, Antimicrobial Agents and Chemotherapy.
[9] M. Krystal,et al. Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects , 2010, Antimicrobial Agents and Chemotherapy.